bad medicine for six pharma firms

Bad medicine for six pharma firms

Six pharmaceutical firms in Vietnam have violated regulations on medicine material trading, a government investigation has revealed.
pharma firms in fine health

Pharma firms in fine health

Foreign pharmaceutical firms are finding Vietnam just the medicine.
incentives ahead for pharma industry

Incentives ahead for pharma industry

Vietnam’s pharmaceutical industry has reached level three under the World Health Organisation’s classification, as the country can now produce some basic raw materials. However, it has yet to fully develop raw material production, as it cannot compete with imported materials.
pharma to experience robust growth

Pharma to experience robust growth

Vietnam healthcare market size is estimated to reach $23.7 billion and grow at an average rate of 7.5 per cent annually from 2023 to 2028. Healthcare expenditure per capita is also projected to increase from $237 to $328 in that time.
competition within asean for pharma investment

Competition within ASEAN for pharma investment

With an ageing population, rising disease burden, and advancements in healthcare science, the global pharmaceutical market has seen significant growth in recent years. In 2023, the total market was estimated at $1.6 trillion, an increase in over $100 billion compared to 2022. As one of the largest and fastest-growing industries, the sector drives healthcare innovation globally.
pharma innovation can come from global experience

Pharma innovation can come from global experience

Innovation has become an inevitable trend in the pharma-healthcare sector, which requires new approaches to tap into its potential and encourage stakeholders to join in. Trinh Van Lau, chairman of the Vietnam Pharmaceutical Companies Association, talked to VIR’s Tung Anh about the factors in need to achieve its long-term vision.
pharma giants gaining big in 2022

Pharma giants gaining big in 2022

International pharma giants have reported strong results for the first half of 2022, with new plans in the pipeline from many of them in this country.
overseas touch lends to pharma gains

Overseas touch lends to pharma gains

Vietnam’s pharma giants are growing with new strategies from foreign leadership, easing local doubts over the possible disappearance of local strong brands.
dreaming big for the vietnamese pharma industry

Dreaming big for the Vietnamese pharma industry

Vietnam has prioritised advancing its pharmaceutical industry, with a particular focus on developing a domestic generic industry to meet the demands of its citizens.
pharma giants beat revenue expectations

Pharma giants beat revenue expectations

Pharmaceutical companies like Pfizer, Novartis, Roche, and GSK performed well in the first three quarters of 2021, with plans to venture further into the lucrative Vietnamese market.
pharma industry picks up the pace in digital

Pharma industry picks up the pace in digital

Offline to online trends are being sped up among pharma stakeholders, which is expected to benefit the development of the pharma supply chain in the long run.
swings and roundabouts for pharma groups so far in 2021

Swings and roundabouts for pharma groups so far in 2021

With risks from interruption of the medical ingredient supply chain and losses in the hospital channel, the Vietnamese pharma industry experienced a topsy-turvy first half of 2021, with potential growth set to focus on mergers and acquisitions.
open doors for pandemic related pharma imports

Open doors for pandemic-related pharma imports

The Ministry of Health has opened the doors wider for more import of biology products and medical equipment for coronavirus diagnostic tests, helping both domestic and international suppliers bulk up their presence in the country.
pharma groups redouble patient centric efforts

Pharma groups redouble patient-centric efforts

Driven by 2020’s highlights, international pharma giants are planning to deliver more vital medicines and vaccines to Vietnam in 2021 to tap into local demands and enable the country to weather future crises.
popular pharma products withdrawn by multinationals

Popular pharma products withdrawn by multinationals

Multinationals like Sanofi, GSK, Adamed Pharma, and Merck Sharp & Dohme have requested marketing authorisation withdrawal of some pharmaceuticals, with it being unclear if the quality of some popular items is an underlying issue.